- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Waldenstrom macroglobulinemia
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 2081KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 760KB)
Zanubrutinib – July 2021
Zanubrutinib (WM): Capsule 80 mg; Brukinsa®
Last updated
30 May 2025